Compare MDAIW & BCTXZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MDAIW | BCTXZ |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | 78 | 4 |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | N/A |
| IPO Year | N/A | N/A |
| Metric | MDAIW | BCTXZ |
|---|---|---|
| Price | $0.47 | $0.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 35.6K | N/A |
| Earning Date | 02-27-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,264,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 44.52 | N/A |
| 52 Week Low | $0.08 | N/A |
| 52 Week High | $0.90 | N/A |
| Indicator | MDAIW | BCTXZ |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | N/A |
| Support Level | $0.40 | N/A |
| Resistance Level | $0.65 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 33.58 | 0.00 |
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.